Hebo Pharmaceutical-B (02142) announced results for the year ended December 31, 2023, and the group obtained revenue...
Zhitong Finance App News, and Platinum Pharmaceutical-B (02142) announced the results for the year ended December 31, 2023. The group achieved revenue of US$89.502 million, an increase of 120.13% over the previous year; profit attributable to the owner of the parent company was US$22.797 million, with a loss of US$137 million in the same period last year; and profit per share was US$0.03.
The company's revenue mainly includes molecular licensing fees, research service fees and technology licensing fees. The increase in revenue is mainly due to licensing cooperation agreements between the company and Seagen, Cullinan and Colon Biotech.
Research service agreements with a total value of US$6.4 million have been successfully signed for the year ending December 31, 2023. Research service fees for the year ended 31 December 2023 were 3.2 million US dollars, an increase of 300.0% compared to $800,000 for the year ended 31 December 2022.